Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.
• Age ≥18 and ≤75 years old (calculated based on the date of signing informed consent);
• Diagnosed as drug-resistant/relapsed non-small cell lung cancer;
• After at least two systemic treatments and the disease progresses;
• According to the efficacy evaluation criteria of solid tumors (RECIST 1.1), at least one lesion that has not received radiation therapy, has not received other local therapies, and can obtain tumor tissue (can be from a single lesion source or multiple lesions combined) is used for organoid establishment;
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-1;
• Expected survival time\>3 months;
• Before a tumor sample can be taken, there must be a record of disease progression on imaging after the previous treatment.;
• The patient has informed consent and signed a written consent form;
• The patients had good compliance and willingly followed the study plan, including scheduled visits, treatments, laboratory tests, and other research steps.